Adaptive Biotechnologies (ADPT) Accounts Payables (2018 - 2026)

Adaptive Biotechnologies has disclosed Accounts Payables across 9 years of filings, most recently posting $9.6 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $9.6 million, up 51.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.6 million (up 51.13% YoY), and the FY2025 annual result was $6.5 million, down 10.98% from the prior year.
• Accounts Payables came in at $9.6 million for Q1 2026 at Adaptive Biotechnologies, up from $6.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $12.2 million in Q1 2024 to a low of $2.7 million in Q2 2022.
• The 5-year median for Accounts Payables is $7.3 million (2024), against an average of $7.3 million.
• Across the five-year window, Accounts Payables tumbled 55.36% in 2022 and surged 236.88% in 2023, its largest moves.
• Adaptive Biotechnologies' Accounts Payables stood at $8.1 million in 2022, then dropped by 4.52% to $7.7 million in 2023, then declined by 5.88% to $7.3 million in 2024, then dropped by 10.98% to $6.5 million in 2025, then surged by 48.68% to $9.6 million in 2026.
• The last three Accounts Payables figures came in at $9.6 million (Q1 2026), $6.5 million (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.